Tag Archives: BLRX

Top Heal Care Stocks To Invest In 2018

The natural gas and solar sectors will survive and maybe even thrive in the wake of President Donald Trumps decision last week to withdraw from the Paris climate accord.

Trump said Thursday that the U.S. will leave the Paris accord because it is very unfair, at the highest level, to the United States. Staying in the agreement would pose serious obstacles for the U.S. as it begins the process of unlocking the restrictions on Americas abundant energy reserves, he said.

Top Heal Care Stocks To Invest In 2018: PetSmart Inc(PETM)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Blue Buffalo Pet Products now roughly back up to its IPO close for retail investors while fresh pet food peer Freshpet Inc (NASDAQ: FRPT) is well below IPO levels and pet stocksCentral Garden & Pet Co (NASDAQ: CENT) andPetmed Express (NASDAQ: PETS) have been the best performers in the pet sector after PetSmart (NASDAQ: PETM) was acquired by a private equity group:

  • [By Peter Graham]

    A long term performance chart shows Blue Buffalo Pet Products roughly back up to its IPO close for retail investors while fresh pet food peer Freshpet Inc (NASDAQ: FRPT) isstill below IPO levels and pet stocksCentral Garden & Pet Co (NASDAQ: CENT) andPetmed Express (NASDAQ: PETS) have been much stronger performers in the pet sector after PetSmart (NASDAQ: PETM) was acquired by a private equity group:

Top Heal Care Stocks To Invest In 2018: Zions Bancorporation(ZION)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    In the super-regional banks that are not money center banks, Regions Financial Corp. (NYSE: RF) was up 6.3% at $13.22, and Zions Bancorporation (NASDAQ: ZION) was last seen up 3.8% at $38.30. They would both do better with lower regulatory costs and be able to better compete against larger banks when their stress test results had not been as strong.

  • [By Nelson Hem]

    See what Barron's feels the prospects are for Energy Transfer Partners LP (NYSE: ETP) if it cuts its distribution and dumps its general partner, and salesforce.com, inc. (NYSE: CRM) with its generous potential upside. Also whether regional banks like Zions Bancorp (NASDAQ: ZION) could see a boost from a proposed regulatory change, and the sweetheart deal the Koch brothers got with Meredith Corporation (NYSE: MDP).

Top Heal Care Stocks To Invest In 2018: Matrix Service Company(MTRX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Matrix Service Co (NASDAQ: MTRX) shares were also up, gaining 16 percent to $18.58 as the company posted better-than-expected Q4 results.

    Equities Trading DOWN

Top Heal Care Stocks To Invest In 2018: BioLineRx Ltd.(BLRX)

Advisors’ Opinion:

  • [By William Romov]

    Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biopharmaceutical stockBioline RX Ltd (NASDAQ: BLRX) as a speculative buy:

Top Heal Care Stocks To Invest In 2018: Panera Bread Company(PNRA)

Advisors’ Opinion:

  • [By Seth McNew]

    Other companies have followed suit with great success, including PaneraBread (NASDAQ:PNRA), which has focused on improving the customer experience, including via shorter wait times. Panera 2.0 was largely successful because of the company’s focus on its digital strategy and Chipotle looks to be doing the same thing.

  • [By Ben Levisohn]

    Keurigs plight (actually, JABs) is worsening, with the K-cup market slowing to almost no growth now, and Keurig continuing to lose own brands share. Starbucks (SBUX) echoed the notion of a K-cup market slowdown at its seminar on Wednesday (and is guiding for its [consumer packaged goods, or CPG,] growth below recent trends), but it expects to increase its share of total CPG coffee to 20% from 15%. Come early February it will be a year since the closing of the Keurig deal for JAB Holdings. The pressure on JAB is more significant if we take into account the high leverage of the deal (JAB contributed one fourth of the $12Bn price tag). It is a tough predicament. On the one hand we argue that to make that deal work, they need to buy more (own) brands either from the retail channel (that can be extended to CPG: Dunkin (DNKN)? Panera (PNRA)?), or outright buy CPG brands (like the entire Kraft Heinz portfolio, and or Tata Groups Eight OClock brand). But can/how do they fund these deals? Maybe Mars and Warren Buffett (Mars is involved in office coffee with Starbucks), private equity, and or 3G can help? While this note is not about Positive-rated Mondelez, we have mentioned before a scenario where Kraft Heinz buys Mondelez and partly funds the deal by selling its own CPG coffee business (~$3Bn we say) to JAB as well as divests the Mondelez 20% plus stakes in Keurig (North America) and Jacobs Douwe Egberts (Western Europe), which together at this stage are worth ~$7-8Bn. But, yes, JAB will need deep-pocket partners and generous lenders. Net, JAB needs to do something soon.

  • [By Lisa Levin]

    Shares of Panera Bread Co (NASDAQ: PNRA) got a boost, shooting up 14 percent to $312.29 after the company agreed to be acquired by JAB for $7.5 billion.

Hot Medical Stocks To Own For 2018

Cell Medx Corp (OTCBB: CMXC) is in the news for insider trading. Reading a headline with insider trading generally sends chills, especially if you are the part of the management team of said company. But lets consider for a moment that this could be a buy opportunity, or at least an event worthy of shining the spotlight on a small(ish) bio-tech firm.

Cell Medx Corp (OTCBB: CMXC) is an early stage bio-tech firm focusing on the discovery, development and commercialization of therapeutic products. With treatments for diabetes, Parkinsons Disease and high blood pressure in their wheelhouse, Cell Medx is plugged into three of the most significant medical conditions that affect the population.

The company recently announced it had completed the registration process with the FDA, and that it is conducting ongoing clinical trials for a diabetes therapy. According to their most recent financials, they eliminated over $800k of liabilities from their balance sheet, and they have a strong cash reserve, indicators that they are well positioned for reverse mergers or acquisition by a larger, more established company.

Hot Medical Stocks To Own For 2018: Nuveen Select Tax Free Income Portfolio(NXP)

Advisors’ Opinion:

  • [By Eric Volkman]

    Income investors might be wary of Qualcomm, as the company loves to spend its money — at times, its dividend payouts and share buybacks have exceeded free cash flow. Compounding that matter, the company should soon close the door on its acquisition of European peer NXP Semiconductor (NYSE:NXP), a deal with an estimated enterprise value of $47 billion.

Hot Medical Stocks To Own For 2018: Radient Technologies (RTI)

Advisors’ Opinion:

  • [By Matthew Briar]

    There’s an old business adage…. it’s not so much what you know, but who you know. If that’ s truly the case (and it is), then shareholders in Radient Technologies Inc (CVE:RTI) should be elated. The newest member of the Board of Directors that not already knows a lot of the right people, but has pretty much done all of things Radient would like to accomplish in the near future. That is, he was on the board for another ingredient and chemical company that was eventually acquired, but he also holds a masters degree in engineering. He can do it all, understanding the art and science of the business.

    It’s yet another reason for RTI investors to be enthused.

    Radient Technologies isn’t exactly a new company, but it’s relative notoriety is a fairly new phenomenon.

    The organization, in simplest terms, has developed an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along.

    Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which drives out the targeting ingredient or component much faster than more conventional extraction methods. In fact, the pressure-driven process outperforms the conventional extraction on pretty much every front. That is, the technique reduces the extraction time from hours to minutes, delivers a higher active ingredient purity, increases the recovery of actives from often scarce biomass, and uses much less solvent and energy than the more typical approach.

    The technique can, and already has, created natural ingredients for global customers across a range of industries, including food and beverage, nutrition, supplements, pharmaceuticals and cosmetics.

    The company’

  • [By Matthew Briar]

    Although the past several years have been very good ones for the cannabis — marijuana and hemp — industry, it’s still mostly being done in an old, artisan-style fashion. Most companies haven’t figured out a way of scaling up their outputs by improving their operating/production efficiency, even though the market’s growth has merited. Radient Technologies Inc (CVE:RTI) represents that next evolution of the cannabinoid business, introducing a new approach to extracting cannabinoids from cannabis plants that will not only improve yields, but create a superior, purer product.

    Canada-based Radient Technologies has developed — and patented – an ingredient-extraction process called microwave assisted processing, or “MAP,” for short. As the name implies, the use of radio microwaves helps the extraction process along. To fully appreciate why it matters, however, one has look at the approach other ingredients suppliers are utilizing now.

    With current approaches to create ingredients from an appropriate source, the material with the target compound or molecule in it is soaked in a solvent, heated to 50 degrees Celsius (or more), and over the course of several hours, the desired ingredient diffuses into the solvent. After filtration, drying, and other processing, that ingredient is finally isolated and then collected.

    It works, but it’s hardly ideal. Aside from the fact that this technique doesn’t work very well at large scale, yields are relatively low. Worse, a lot of things you don’t want to extract can still be found in the extract, lowering the quality and purity of the ingredient.

    Radient Technologies’ microwave assisted processing changes all of this.

    Using its patented MAP process, Radient is able to selectively deposit microwave energy into a biomass (source material) and heat the target elements while leaving other materials in the mix unaltered. The near-instantaneous “in-core” heating that occurs creates pressure which

  • [By Jim Robertson]

    Small cap Radient Technologies (CVE: RTI) is focused on extracting, isolating and purifying food/nutraceutical ingredients (colourings, flavourings, preservatives etc) and pharmaceutical raw materials from its20,000 square foot manufacturing plant in Edmonton, Alberta. The Companyworks with global brands across a range of industries (including Food and Beverage, Nutrition and Supplements, Pharmaceuticals, Personal Care and Cosmetics and Biofuel) andengageswithits clients in three distinct phases:

  • [By Matthew Briar]

    At first glance, a new set of rules from the Drug Enforcement Agency unveiled in the middle of December looked like it posed a problem for cannabis-newcomer Radient Technologies Inc (CVE:RTI). By assigning a controlled substances code number to ‘marijuana extract,’ simultaneously distinguishing (and acknowledging the differences of marijuana, hemp and their derivatives as Schedule I substances. As the ruling’s language explained, “This code number will allow DEA and DEA-registered entities to track quantities of this material separately from quantities of marihuana. This, in turn, will aid in complying with relevant treaty provisions.”

    It presents something of an uncertainty, as it was not clear of the DEA also meant hemp and cannabis extracts when it used the term ‘marijuana extract.’ After all, the Drug Enforcement Agency has thus far done a poor job of distinguishing between hemp and marijuana, but has generally erred on the side of grouping everything as marijuana…. even if it didn’t cause a ‘high,’ and even if it did provide a medical benefit. If that was indeed the case, Radient Technologies may well be a non-starter in its quest to get into the cannabis business.

    No need to worry. Though it took weeks to get some much-needed clarification, the DEA has finally explained what it was saying two months ago. Indeed, the new ruling may actually help the medical marijuana — cannabis — along. DEA spokesman Russ Baer said in an e-mail to The Cannabist, “(The rule change) recognizes that there is a potential medical benefit to some of the cannabinoids.”

    Some still worry the wording of the law essentially, even if unintentionally, puts cannabinoids (or CBD) under the purveyance of the DEA; it’s currently not. Even so, if nothing else the ruling has the government moving towards clarity, after acknowledging CBD — the healthy version of the cannabis, and not the one that gets you high — has medical value. The next step is clarifying ho

  • [By James E. Brumley]

    Some of the stories about how cannabis has changed lives for the better are nothing less than astounding. Take Illinois resident Darren Miller as an example. In 2015 Miller was diagnosed with lung cancer that was later deemed terminal. Miller underwent chemotherapy, without much hope, but also began using high-THC Indica cannabis oil. Miller is alive today, and arguably shouldn’t be.

    Then there’s Floridian Branden Petro. Not only does Petro suffer epilepsy, he commonly experiences seizures stemming from the condition. Nothing has stopped the seizures as quickly or effectively as 200 milligram worth of THC cannabis oil, administered as a nasal spray. Within 20 seconds of using it, it’s as of the seizure never happened.

    And there are millions of other such (and less dramatic) examples, all pointing in the same direction – cannabis has medical value on multiple fronts. Not facilitating its commercialization is a wasted opportunity.

    It’s a notion that’s far from lost on the people that have built Canadian-based Radient Technologies Inc (CVE:RTI) from the round up, recently inking a deal with supplier of cannabinoid extracts, Aurora Cannabis.

    It’s a real accolade. Aurora is one of the largest licensed producers of medical cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), and recently began construction on an unprecedented 800,000 square foot production facility in Leduc County, Alberta. This facility, known as “Aurora Sky”, is anticipated to be capable of producing in excess of 100,000 kg of high-quality, low-cost marijuana per year.

    In most regards though, Radient Technologies is the big winner of the deal, as the partnership is apt to put its high-tech facility in full demand, helping to advance the advent of cannabis in all its potential glory.

    It’s a rather amazing science, really. Radient Technologies uses an ingredient-extraction process called microwave assisted proc

Hot Medical Stocks To Own For 2018: Federal-Mogul Holdings Corporation(FDML)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Mario Gabelli on Monday gained the upper hand in his battle to force Carl Icahn to sweeten his offer for a car-parts manufacturer. Icahn, who owns 82 percent of Federal-Mogul (NASDAQ: FDML), offered $9.25 a share for the remaining stake but fell way short after Gamco Investors boss Gabelli — who has a leading stake in Federal-Mogul — pressed for a higher price.

Hot Medical Stocks To Own For 2018: BioLineRx Ltd.(BLRX)

Advisors’ Opinion:

  • [By William Romov]

    Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biopharmaceutical stockBioline RX Ltd (NASDAQ: BLRX) as a speculative buy:

Hot Medical Stocks To Own For 2018: Brown & Brown, Inc.(BRO)

Advisors’ Opinion:

  • [By Ben Levisohn]

    BMO also upgraded Arch Capital Group (ACGL), Brown & Brown (BRO), and Travelers (TRV).

    Shares of American International Group have declined 0.4% to $65.60 at 3:36 p.m. today, whileArch Capital Group has gained 2% to $87.90,Brown & Brown has advanced 0.5% to $44.65, andTravelers has risen 1.3% to $120.79.

Hot Medical Stocks To Own For 2018: 3D Systems Corporation(DDD)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows ExOne Co along with other small cap 3D printing stocks like3D Systems Corporation (NYSE: DDD), Stratasys, Ltd (NASDAQ: SSYS) and Voxeljet AG (NYSE: VJET) all peaking in 2013/2014 with the bubble clearly bursting since then:

  • [By Jack Delaney]

    Here are 10 virtual reality stocks to watch in 2017, with today’s opening price (Feb. 22) and the year-to-date (YTD) return thus far:

    3D Systems Corp. (NYSE: DDD); $17.12; +26.71% YTDUniversal Display Corp. (Nasdaq: OLED); $71.60; +25.49% YTDAdvanced Micro Devices Inc. (Nasdaq: AMD); $14.30; +24.22% YTDFacebook Inc. (Nasdaq: FB); $133.60; +18.64% YTDAdobe Systems Inc. (Nasdaq: ADBE); $119.67; +15.93% YTDSony Corp. (NYSE ADR: SNE); $31.29; +11.49% YTDAlphabet Inc. (Nasdaq: GOOGL); $848; +7.49% YTDAmbarella Inc. (Nasdaq: AMBA); $57.85; +6.26% YTDMicrosoft Corp. (Nasdaq: MSFT); $64.33; +3.16% YTDRockwell Collins Inc. (NYSE: COL); $93.97; +0.97% YTD

    The virtual reality industry could reach $33.9 billion in value by 2022, which is why virtual reality stocks are more popular than ever.

  • [By Beth McKenna]

    While Stratasys’ stock is still down significantly from its all-time high, it’s showing signs of life this year. It’s gained 17% in 2017, through March 3, outpacing rival 3D Systems’ (NYSE:DDD)9.3% gain and the S&P 500’s total return of 6.9%. Shares of 3D Systems had been riding higher in 2017, through plummeted 10% after the company announced earnings on Feb. 28. Quarterly revenue and 2017 revenue guidance came in lighter than Wall Street analysts were expecting.

day trading penny stocks

15 Most Overlooked Tax Deductions: 2017

For Fiduciary Rule, Morningstar Sees Up to $150M in Annual Class Action Settlements

Top 10 Cities for Millennial Homebuyers

Wells Fargo & Co. said credit-card applications dropped 55 percent in February from a year earlier, the biggest decline since a scandal involving fake accounts erupted in September.

Retail customers opened 43 percent fewer checking accounts in February, marking the sixth straight month of declines since regulators fined the bank over the creation of unauthorized accounts.

Copyright 2017 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

The service, to be called Intuitive Investor, aims to bring in new, younger clients to its wealth management unit.

You are signed up!

ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Resources 5 Steps to Eradicate Text Messaging Risk

In this White Paper, we share five steps to help you build a risk management program that enables the benefits of text messaging while protecting…

day trading penny stocks: BioLineRx Ltd.(BLRX)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biopharmaceutical stockBioline RX Ltd (NASDAQ: BLRX) as a speculative buy:

  • [By William Romov]

    Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

day trading penny stocks: Vermillion, Inc.(VRML)

Advisors’ Opinion:

  • [By Alex McGuire]

    Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…

    Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%

    The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.

day trading penny stocks: Bill Barrett Corporation(BBG)

Advisors’ Opinion:

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Petroleo Brasileiro S.A.- Petrobras (NYSE: PBR): Free Stock Analysis Report
     
    Bill Barrett Corporation (NYSE: BBG): Free Stock Analysis Report
     
    Northern Oil and Gas, Inc. (AMEX:NOG): Free Stock Analysis Report
     
    Rice Midstream Partners LP (NYSE: RMP): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Canadian Natural Resources Limited (NYSE: CNQ): Free Stock Analysis Report
     
    Cenovus Energy Inc (NYSE: CVE): Free Stock Analysis Report
     
    Bill Barrett Corporation (NYSE: BBG): Free Stock Analysis Report
     
    ConocoPhillips (NYSE: COP): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

  • [By Lisa Levin]

    On Thursday, the energy sector proved to be a source of strength for the market. Leading the sector was strength from Halcon Resources Corp (NYSE: HK) and Bill Barrett Corporation (NYSE: BBG).

day trading penny stocks: PNC Financial Services Group, Inc. (The)(PNC)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Who is “the market” and how does it “want” to go down? Where’s the commandment that says stocks have to go lower? Who decides that today people who own stocks are by and large going to lose money? And why, of all things, does the market not want to go higher? Didn’t the CEO of the biggest bank, JPMorgan (JPM) , say things are great? Didn’t Wells Fargo (WFC) , after all of that scandal, still show some growth, a sign that it is putting the rough patch behind it? Didn’t Citigroup (C) have its best quarter in years? Wasn’t PNC Financial (PNC) even better, clear triumphs on every single line item? The word “perfect” comes to mind, as in Perfect National Corp. (Wells Fargo and Citigroup are part of TheStreet’s Action Alerts PLUS portfolio.)

  • [By Lisa Levin] Related WFC Why Bank ETFs Fell On Friday Despite Decent Earnings Phil's Stock World: Funtime Friday Earnings Season Starts Today Rising Book Values and Margins of Safety (GuruFocus)
    Related C Earnings Preview: Financial Giants BAC, GS, And MS Report Q2 Results This Week Why Bank ETFs Fell On Friday Despite Decent Earnings Palo Capital, Inc. Buys Citigroup Inc, Schlumberger, NetApp Inc, Sells Citrix Systems Inc, … (GuruFocus) Companies Reporting Before The Bell
    Wells Fargo & Co (NYSE: WFC) is estimated to report quarterly earnings at $1.02 per share on revenue of $22.51 billion.
    Citigroup Inc (NYSE: C) is projected to report quarterly earnings at $1.26 per share on revenue of $17.71 billion.
    JPMorgan Chase & Co. (NYSE: JPM) is expected to report quarterly earnings at $1.65 per share on revenue of $25.61 billion.
    PNC Financial Services Group Inc (NYSE: PNC) is projected to report quarterly earnings at $2.02 per share on revenue of $4.00 billion.
    First Republic Bank (NYSE: FRC) is estimated to report quarterly earnings at $1.1 per share on revenue of $675.70 million.
    First Horizon National Corp (NYSE: FHN) is projected to report quarterly earnings at $0.28 per share on revenue of $337.89 million.

     

  • [By Ben Levisohn]

    We believe investors should continue to own three types of bank stocks: “Return of Capital (RC) Stocks”, “Risk On (RO) Stocks”, and “Multiple Revaluation (MR) Stocks.” RC stocks include M&T Bank (MTB), PNC Financial Services Group (PNC), and SunTrust Banks (STI); RO stocks include Bank of America, Popular (BPOP), Citigroup, JPMorgan, and KeyCorp (KEY); and MR stocks include BB&T (BBT) and PNC Financial Services Group (PNC).

day trading penny stocks: Silicom Ltd(SILC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Silicom Ltd. (NASDAQ: SILC) shares were also up, gaining 17 percent to $45.45. Silicom reported a major new design win with $17 million in purchase orders.

investment stocks

Twitter stock looks like it is only headed lower in the coming months. Here are 3 reasons why you might want to exit TWTR stock.
Flickr

Shares of San Francisco, California-based Twitter Inc (NYSE:TWTR)have had a tough time this year, falling by close to 12%, even as a host of tech names have enjoyed a great run. While the consistent decline in the stock price in recent times may seem like an opportunity to enter the stock, investors could be better off exiting TWTR stock on any rebound. Unless you have a huge risk appetite and are betting on an acquisition, buying now or continuing to hold stock may not make a lot of sense. Here are 3 reasons why you might want to sell TWTR shares completely.

investment stocks: FLIR Systems, Inc.(FLIR)

Advisors’ Opinion:

  • [By Jim Robertson]

    Small cap homeland security and screening stocks like FLIR Systems (NASDAQ: FLIR), OSI Systems (NASDAQ: OSIS),Varex Imaging Corp (NASDAQ: VREX) and Patriot One Technologies (OTCQB: PTOTF) stand to benefit fromTrumps focus on border andinternal security in general. Heres what you need to know about all four:

  • [By Peter Graham]

    Oregon based small cap FLIR Systems (NASDAQ: FLIR) was founded in 1978 as a world-leading maker of sensor systems that enhance perception and heighten awareness, helping to save lives, improve productivity, and protect the environment. Through its nearly 3,500 employees, the Company’s vision is to be “The World’s Sixth Sense” by leveraging thermal imaging and adjacent technologies to provide innovative, intelligent solutions for security and surveillance, environmental and condition monitoring, outdoor recreation, machine vision, navigation, and advanced threat detection.

  • [By Teresa Rivas]

    Flir Systems(FLIR) was the biggest loser in the S&P 500 on Tuesday, but the stock recouped all its losses Wednesday, and then some.

    Getty Images

    Flir Systems gained $2.78, or 8.1%, to close at $36.93.

    The company’sdisappointing fourth-quarter earnings report was forgotten when it announced that the U.S. Coast Guard awarded it a $50 million contract. Flir will provide marine electronics systems for more than 2,000 Coast Guard vessels for its Scalable Integrated Navigation Systems 2 (SINS-2) program over a five-year period, with the option for extended delivery for an additional five years.

    Even before the news, Imperial Capital’sEd Mally was bullish on the stock’s prospects, who raised his price target on the stock by $2, to $38:

    Although we believe that some may still consider Flir as just a premier provider of very high-end cameras in the bellies of Bell Helicopters or border towers in a lumpy government sector, this 35-year-old company is a global leader in thousands of infrared detector cores and thermography equipment markets and also provides lower priced products to commercial and consumer security customers as well as other customers.

    Flir is up 2% so far this year.

    Coty(COTY) was the hottest stock in the S&P 500 yesterday.

investment stocks: TeleNav Inc.(TNAV)

Advisors’ Opinion:

  • [By Lisa Levin]

    Telenav Inc (NASDAQ: TNAV) shares were also up, gaining 16 percent to $8.15 after the company reported the settlement of patent lawsuit. The company projects Q2 revenue of $51 million to $52 million and loss of $0.30 per share to $0.28 per share.

investment stocks: LendingClub Corporation(LC)

Advisors’ Opinion:

  • [By Lisa Levin]

    LendingClub Corp (NYSE: LC) shares dropped 14 percent to $3.66 following weak Q4 and FY18 guidance.

    Shares of Duluth Holdings Inc (NASDAQ: DLTH) were down 16 percent to $16.20 after the company posted downbeat Q3 results.

  • [By Mark Balson]

    Lending Club’s (LC) acting CEO Scott Sanborn replies to company’s investors and assures that company is in strong financial position and enough cash flow in balance sheet. “Cash and securities amount to $868 million.” He replies.

    Scott Sanborn also ensured company’s investors through e-mail who buys company’s loans, “We plan to be around for many years.”

    But as per company’s website Leading Club’s loan investors, “May not receive full amount, if it goes out of business.” Or could see delayed payments. 

investment stocks: BioLineRx Ltd.(BLRX)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biopharmaceutical stockBioline RX Ltd (NASDAQ: BLRX) as a speculative buy:

  • [By William Romov]

    Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

investment stocks: Retail Properties of America, Inc.(RPAI)

Advisors’ Opinion:

  • [By Ant贸nio Costa]

    Retail Properties of America Inc (NYSE: RPAI) has been in an impressive rebound since the lows of August and the stock price action continues to become Bullish. However, RPAI has run into the downtrend line resistance again and this could lead to a brief period of sideways consolidation or price correction from current levels. On watch.

investment stocks: Fortive Corporation (FTV)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Fortive Corp. (NYSE: FTV) was started as Sector Perform at RBC Capital Markets.

    Herman Miller Inc. (NASDAQ: MLHR) was raised to Market Perform from Underperform at Raymond James.

  • [By Ben Levisohn]

    Last year at this time, we said we can only hope for a bit more growth, and at least bottoming for many of those stubborn energy/commodity/industrial end markets, less FX headwind, pricing support and cost reduction plus smart capital deployment, be it M&A, Capex, and/or buybacks/dividends that might actually lead to stock outperformance. In fact, we did get a bit more growth and many of the stubborn end markets appear to have bottomed, while most of those other items also did play out. The stocks under our coverage outperformed the S&P (which was up >10% itself) by more than 14% on average, led byIngersoll-Rand (+37%),Rockwell Automation (+31%),Eaton (+30%) and Fortive (FTV) (+26%) with Allegion (ALLE) (-2%) andGeneral Electric (+2%) the worst performing.

5 Top Biotech Penny Stocks to Buy with Huge Catalysts in January 2018

Few investments have the profit potential of penny stocks, which are stocks that trade under $5 per share.

Just take a look at Marathon Patent Group Inc. (Nasdaq: MARA), which climbed an astounding 341% during the four trading days of Thanksgiving week.

Biotech penny stocks are especially attractive since successful clinical trial results for their drugs can often send their share prices soaring 300%-plus.

That’s why today we’re giving you five of the top biotech penny stocks to buy that are all reporting clinical trial results in January 2018.

If a stock’s clinical trial results are positive, then the stock can soar. For example, the first stock on this list shot up 213% in July after the U.S. Food and Drug Administration (FDA) accepted the resubmission of its New Drug Application (NDA) for one of its drugs.

Receiving FDA approval for an NDA is typically the last major benchmark a drug must pass before it can be launched.

While these stocks have huge profit potentials, you must keep in mind that penny stocks are very speculative investments. They often see big pullbacks after making large gains.

That’s why Money Morning recommends that no more than 2% of your stock portfolio consist of such risky investments.

But if you’re willing to take the risk, some of these stocks could bring you profits of over 300% next year.

FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

Now get comfy and grab your calendar, because here’s the first biotech penny stock on our list today…

Biotech Penny Stocks to Buy for January, No. 5: Aeterna Zentaris Inc.

Currently trading at $2 per share, Aeterna Zentaris (Nasdaq: AEZS) makes the drug Macrilen as a potential treatment for growth hormone deficiency in adults.

On July 18, the company announced the FDA accepted its NDA for Macrilen for review. This news sent AEZS shares up from $1.02 to $3.20 in just three trading days, for a gain of 213%.

top biotech penny stocks to buymoneymorning.com/wp-content/blogs.dir/1/files/2017/12/spilling-medicine-75×113.png 75w, moneymorning.com/wp-content/blogs.dir/1/files/2017/12/spilling-medicine.png 300w” sizes=”(max-width: 200px) 100vw, 200px” title=”top biotech penny stocks to buy” />

Still, before Aeterna can launch the drug Macrilen, its resubmitted NDA must be approved by the FDA. The FDA will announce if it approves Aeterna’s resubmitted NDA on Dec. 30.

Company officials are confident the company will be able to launch Macrilen sometime in the first quarter of 2018.

Keep an eye on AEZS shares leading up to the Dec. 30 announcement, and buy only if you believe the FDA will approve the NDA.

Up next is a stock with a drug that has three chances to pass phase 3 clinical trials…

Biotech Penny Stocks to Buy for January, No. 4: Axsome Therapeutics Inc.

Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer’s disease, and chronic pain.

Unlike other biotech penny stocks, shares of AXSM aren’t “all in” on just one drug’s results.

Axsome has at least three different drugs in clinical trial testing, meaning it has a greater chance of having at least one of its drugs pass. This makes shares of AXSM less risky than a biotech penny stock with only one drug in development.

Specifically, we’re going to focus on Axsome’s AXS-02 drug, which is in two separate phase 3 clinical trials to treat complex regional pain syndrome and knee osteoarthritis associated with bone marrow lesions. The results for these two clinical trials are expected in late December or early January.

VideoMeet the Trading Expert Who Could Help Make You a Millionaire

If the AXS-02 drug passes phase 3 clinical trials, the stock could jump significantly.

The company also has a second drug, AXS-05, currently in phase 3 clinical trials for the treatment of treatment-resistant depression. Those results are expected sometime in the first half of 2018, so it’s likely that AXS-02’s results will come out first.

The next company we’ll show you is the cheapest on this list…

Biotech Penny Stocks to Buy for January, No. 3: BioLine Rx Ltd.

Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

BioLine has partnerships with major pharmaceutical companies that help bring some of these drugs to launch once they gain some initial success in clinical trials. These partners include Novartis AG (NYSE: NVS) and Merck & Co. Inc. (NYSE: MRK).

Like Axsome Therapeutics, BioLine is less risky than other biotech penny stocks that only have a single drug in development or single partner. But BioLine’s risk profile is even more diverse, with eight drugs in development and multiple major partnerships to help support it.

The company’s leading drug BL-8040 is being tested in three different phase 2 clinical trials in 2018. The first trial is for the drug’s treatment of pancreatic cancer. Partial data of the trial will be presented between Jan. 18 and 20 at the ASCO 2018 Gastrointestinal Cancers Symposium.

Next up is a company which makes a drug that could provide millions of Americans with the relief they so deserve…

Join the conversation. Click here to jump to comments…